Ulisse Biomed S.p.A. (UBM.MI)
EUR 0.76
(-2.56%)
EUR 0.76
(-2.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -4.79 Million EUR | -266.8% |
| 2022 | -1.3 Million EUR | -116.66% |
| 2021 | -603.59 Thousand EUR | -371.89% |
| 2020 | 222 Thousand EUR | 120.56% |
| 2019 | -1.08 Million EUR | 44.14% |
| 2018 | -1.93 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.53 Million EUR | 0.0% |
| 2024 Q1 | -1.53 Million EUR | 21.25% |
| 2023 FY | -4.79 Million EUR | -266.8% |
| 2023 Q3 | -1.94 Million EUR | -116.62% |
| 2023 Q4 | -1.94 Million EUR | 0.0% |
| 2023 Q2 | -899.56 Thousand EUR | -100.0% |
| 2023 Q1 | -449.78 Thousand EUR | 42.05% |
| 2022 Q2 | -531.59 Thousand EUR | -100.0% |
| 2022 FY | -1.3 Million EUR | -116.66% |
| 2022 Q3 | -388.07 Thousand EUR | 27.0% |
| 2022 Q1 | -265.79 Thousand EUR | 48.41% |
| 2022 Q4 | -776.14 Thousand EUR | -100.0% |
| 2021 FY | -603.59 Thousand EUR | -371.89% |
| 2021 Q1 | -44.18 Thousand EUR | -116.41% |
| 2021 Q2 | -88.37 Thousand EUR | -100.0% |
| 2021 Q3 | -257.61 Thousand EUR | -191.5% |
| 2021 Q4 | -515.22 Thousand EUR | -100.0% |
| 2020 Q2 | -47.43 Thousand EUR | -100.0% |
| 2020 FY | 222 Thousand EUR | 120.56% |
| 2020 Q3 | 134.64 Thousand EUR | 383.84% |
| 2020 Q1 | -23.71 Thousand EUR | 0.0% |
| 2020 Q4 | 269.27 Thousand EUR | 100.0% |
| 2019 FY | -1.08 Million EUR | 44.14% |
| 2018 FY | -1.93 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ARTERRA BIOSCIENCE | 1.07 Million EUR | 545.741% |
| Philogen S.p.A. | -6.16 Million EUR | 22.142% |